Cost among other factors may deter patients from screening, especially in rural and low-resource settings.

The trial evaluated ONS-5010 in wet age-related macular degeneration patients, and the company plans to resubmit a Biologics License Application in the first quarter of 2025.

City Therapeutics will develop a novel RNAi clinical candidate toward a specific disease target for intravitreal administration.

Study sees a positive association between the dietary inflammatory index (DII) and non-refractive visual impairment among US populations

This trial is designed to evaluate 4D-150 in diabetic macular edema.

The funding will support activities like formal pharmacology and toxicology testing.

The new funding will allow the company to complete its ongoing Phase 2 trial of proprietary nanomedicine, migaldendranib, in patients with wet AMD and DME

OCU400 demonstrated meaningful improvement of 2-line gain (10 letters on ETDRS chart) in low-luminance visual acuity (LLVA) in treated eyes when compared to untreated fellow eyes.

Dr. Frenkel highlights a comprehensive program that covers the latest breakthroughs in glaucoma and cataract surgery to in-depth discussions on AI, retinal treatments, and new drug-delivery platforms, all set against the backdrop of Snowmass, Colorado.

The launch follows a CE Mark received late last year.

The company will prioritize its cash in funding its ongoing Phase 1/2 PRISM clinical trial and Phase 3 4FRONT program.

With this addition, Zeiss completes the Corneal Refractive Workflow, which already includes Visumax 800 and SMILE pro.

Previously, Teva was established as the European commercialisation partner of FYB201, Formycon's biosimilar to ranibizumab (Lucentis).

Whitecap is currently developing 2 therapies for potential use in glaucoma and geographic atrophy.

Several companies have announced new executives and board members appointments as they prepare for growth in 2025.